Discovery advances development of new therapeutic options for cancer and other diseases. A research team led by the University of California, Irvine has engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, which is inherently more stable than DNA, advances the discovery of potentially more powerful, precise therapeutic options to treat cancer and autoimmune, metabolic and infectious diseases.
Read MoreCategory Biology/Biotechnology
Scientists from Duke-NUS Medical School and the University of California, Santa Cruz, have discovered the secret to regulating our internal clock. They identified that this regulator sits right at the tail end of Casein Kinase 1 delta (CK1δ), a protein which acts as a pacesetter for our internal biological clock or the natural 24-hour cycles that control sleep-wake patterns and other daily functions, known as circadian rhythm.
Published in ...
Read MoreAn estimated one in five Americans live with chronic pain and current treatment options leave much to be desired. Feixiong Cheng, Ph.D., Director of Cleveland Clinic’s Genome Center, and IBM are using artificial intelligence (AI) for drug discovery in advanced pain management. The team’s deep-learning framework identified multiple gut microbiome-derived metabolites and FDA-approved drugs that can be repurposed to select non-addictive, non-opioid options to treat chronic pain.
The findings, published in Cell Press, represent one of many ways the organizations’ Discovery Accelerator partnership is helping to advance research in healthcare and life sciences.
Treating chronic pain with opioids is still a challenge due to the risk of severe side eff...
Read MoreA research team from the University of California, Irvine is the first to reveal that a molecule in the brain—ophthalmic acid—unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target for Parkinson’s and other movement diseases.
In the study, published in the October issue of the journal Brain, researchers observed that ophthalmic acid binds to and activates calcium-sensing receptors in the brain, reversing the movement impairments of Parkinson’s mouse models for more than 20 hours.
The disabling neurogenerative disease affects millions of people worldwide over the age of 50...
Read More
Recent Comments